Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection

Annals of Transplantation

Volumn 20, Issue , 2015, Pages 25-35

  Duvoux, Christophe ^a   Villamil, Federico ^b   Renner, Eberhard L ^c   Grazi, Gian Luca ^d   Firpi, Roberto J ^e   Pageaux, Georges ^f   Mullhaupt, Beat ^g   Schirm, Florian ^h   Rauer, Barbara ⁱ   Bernhardt, Peter ⁱ   Levy, Gary ^j  

^a HENRI MONDOR HOSPITAL   (France)

^b HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f HÔPITAL SAINT ELOI   (France)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h DATAMAP GmbH   (Germany)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Cyclosporine; Liver transplantation; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A; RIBAVIRIN; TACROLIMUS; ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DEATH; DIABETES MELLITUS; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; ISHAK KNODELL SCORING SYSTEM; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MULTICENTER STUDY; PATIENT HISTORY OF LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; SCORING SYSTEM; SEPSIS; TREATMENT RESPONSE; VIRUS LOAD; ADOLESCENT; AGED; CLINICAL TRIAL; DRUG COMBINATION; HEPATITIS C, CHRONIC; LIVER TRANSPLANTATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CALCINEURIN INHIBITORS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921299679     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.892032     Document Type: Article

References (42)

1. Samonakis DN, Germani G, Burroughs AK: Immunosuppression and HCV recurrence after liver transplantation. J Hepatol, 2012; 56: 973-83
2. Coilly A, Roche B, Samuel D: Current management and perspectives for HCV recurrence after liver transplantation. Liver Int, 2013; 33(Suppl.1): 56-62
3. Gane EJ: The natural history of recurrent hepatitis and what influences this. Liver Transplant, 2008; 14(Suppl.2): S36-44
4. Martin EF, Huang J, Xiang Q et al: Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database. Liver Transpl, 2012; 18: 914-29
5. van der Meer AJ, Veldt BJ, Feld JJ et al: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 2012; 308: 2584-93
6. Morgan TR, Ghany MG, Kim HY et al., HALT-C Trial Group: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 2010; 52: 833-44
7. Picciotto FP, Tritto G, Lanza AG et al: Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol, 2007; 46: 459-65
8. Tanaka T, Selzner N, Therapondos G et al: Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transpl Int, 2013; 26: 42-49
9. Roche B, Sebagh M, Canfora ML et al: Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl, 2008; 14: 1766-77
10. Ponziani FR, Milani A, Gasbarrini A et al., AISF RECOLT-C Group: Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. Transpl Int, 2013; 26: 281-89
11. Belli LS, Volpes R, Graziadei I et al: Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Dig Liver Dis, 2012; 44: 603-9
12. Berenguer M: Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol, 2008; 49: 274-87
13. Wang CS, Ko HH, Yoshida EM et al: Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant, 2006; 6: 1586-99
14. Xirouchakis E, Triantos C, Manousou P et al: Peyglated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat, 2008; 15: 699-709
15. Gordon FD, Kwo P, Ghalib R et al: Peginterferon-a-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol, 2012; 46: 700-8
16. Firpi RJ, Dong H, Clark VC et al: CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int, 2013; 33: 72-78
17. Duarte-Rojo A, Deneke MG, Charlton MR: Interleukin-28B polymorphism in hepatitis C and liver transplantation. Liver Transpl, 2013; 19: 49-58
18. Handschumacher RE, Harding MW, Rice J et al: Cyclophilin: a specific cytosolic binding protein for cyclosporine A. Science, 1984; 226: 544-47
19. Chatterji U, Bobardt M, Selvarajah S et al: The isomerase active site of cyclophilin A is critical for hepatitis C viral replication. J Biol Chem, 2009; 284: 16998-7005
20. Watashi K, Hijikata M, Hosaka M et al: Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 2003; 38: 1282-88
21. Maniere T, Ethier C, Raymond VA et al: Cyclosporin reduce hepatitis C virus replication in the replicon model. J Hepatol, 2004; 40(Suppl.1): 120
22. Nakagawa M, Sakamoto N, Enomoto N et al: Specific inhibition of hepatitis C virus replication by cyclosporine A. Biochem Biophys Res Commun, 2004; 313: 42-47
23. Firpi RJ, Zhu H, Morelli G et al: Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl, 2006; 12: 51-57
24. Henry SD, Metselaar HJ, Lonsdale RC et al: Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology, 2006; 131: 1452-62
25. Villamil FG, Gadano AC, Zingale F et al: Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: A randomised study of everolimus vs. calcineurin inhibitors. Liver Int, 2013 [Epub ahead of print]
26. Guitard J, Sandres-Saune K, Kamar N et al: Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study. Transplant Proc, 2007; 39: 2603-5
27. Pollard S: Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient. Liver Int, 2004; 24: 402-6
28. Berenguer M, Aguilera V, Prieto M et al: Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl, 2006; 12: 762-67
29. Kim RD, Mizuno S, Sorensen JB et al: Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation. Dig Dis Sci, 2012; 57: 568-72
30. Johnson MW, Washburn WK, Freeman RB et al: Hepatitis C viral infection in liver transplantation. Arch Surg, 1996; 131: 284-91
31. Van der Laan LJ, Hudson M, McPherson S et al: Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. Transplant Proc, 2010; 42: 4573-77
32. Villamil F, Levy G, Grazi GL et al: Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant Proc, 2006; 38: 2964-67
33. Firpi RJ, Soldevila-Pico C, Morelli GG et al: The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci, 2010; 55: 196-203
34. Rabie R, Mumtaz K, Renner EL: Efficacy of antiviral therapy for hepatitis C after transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl, 2013; 19: 36-48
35. Duvoux C, Firpi R, Grazi GL et al: Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. Transpl Int, 2013; 26: 358-72
36. Ishak K, Baptista A, Bianchi L et al: Histological grading and staging of chronic hepatitis. J Hepatol, 1995; 22: 696-99
37. Knodell RG, Ishak KG, Black WC et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981; 1: 431-35
38. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 16: 31-41
39. Chen J, Florian J, Carter W et al: Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology, 2013; 144: 1450-55
40. Selzner N, Renner EL, Selzner M et al: Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation, 2009; 88: 1214-21
41. Gordon FD, Poordad F, Neff GW et al: Baseline, donor, and on-treatment predictors of sustained virologic response in patients treated for recurrent hepatitis following orthotopic liver transplant: subanalysis of the PROTECT study. Hepatology, 2010; 52(Suppl.1): 754A [Abstract 905]
42. Ponziani FR, Milani A, Gasbarrini A et al: Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. Ann Hepatol, 2012; 11: 338-42